MedTrace Logo

VitaFlow™ Transcatheter Aortic Valve System Post-market Study-The LAUNCH Study

NCT04414865 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-06-04

No results posted yet for this study

Summary

The study objective is to evaluate safety and effectiveness/performance of the Microport™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System for the treatment of severe aortic stenosis in the real world settings.

Conditions

  • Aortic Valve Stenosis

Interventions

DEVICE

VitaFlow™ Transcatheter Aortic Valve System

VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set

Sponsors & Collaborators

  • Shanghai MicroPort CardioFlow Medtech Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-26
Primary Completion
2021-12-01
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04414865 on ClinicalTrials.gov